Panel Discussion: The Investment Landscape for CNS Delivery Technologies: Trends, Drivers & Funding Priorities

3:30 pm - Wednesday 2nd December 2026

  • Assess where capital is concentrating across CNS delivery modalities and identify the key scientific and commercial drivers behind investment decisions
  • Define the target product profiles and competitive advantages that make CNS delivery platforms attractive for partnerships and acquisition
  • Evaluate the timelines, capital requirements, and key inflection points for advancing CNS delivery technologies from preclinical development to clinical validation
  • Examine how cost-of-goods, scalability, and risk profiles influence long-term commercial viability and investor confidence

Speakers:

Director, Novel Delivery Technologies
Novartis
Partner
SV Health Investors
Global Director, Research & Technology Search & Evaluation
Daiichi Sankyo
Executive Director Search & Evaluation Neuroscience
Eli Lilly